Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5541
Source ID: NCT02653599
Associated Drug: Ttp273
Title: A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: TTP273|DRUG: Placebo
Outcome Measures: Primary: Change in HbA1c from baseline at 12 weeks, Day 1 to Week 12 | Secondary: Percentage of subjects who achieve HbA1c <7% at 12 weeks, Day 1 to Week 12|Change in body weight from baseline at 12 weeks, Day 1 to Week 12|Change in plasma glucose levels from baseline at 12 weeks, Day 1 to Week 12|Change in lipid Levels from baseline at 12 weeks, Day 1 to Week 12|Change in insulin levels from baseline at 12 weeks, Day 1 to Week 12|Change in C-peptide levels from baseline at 12 weeks, Day 1 to Week 12|Adverse Events, Day 1 to Week 14|Blood Pressure, Day 1 to Week 14|Electrocardiogram Parameters, Day 1 to Week 14|Hematology, Day 1 to Week 14|Blood Chemistry, Day 1 to Week 14|Urinalysis, Day 1 to Week 14|Pulse, Day 1 to Week 14 | Other: Change in glucagon levels from baseline at 12 weeks, Day 1 to Week 12|Change in glucagon-like peptide-1 levels from baseline at 12 weeks, Day 1 to Week 12
Sponsor/Collaborators: Sponsor: vTv Therapeutics
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 174
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2015-12
Completion Date: 2017-01
Results First Posted:
Last Update Posted: 2017-02-10
Locations: Costa Mesa, California, 92626, United States|Encino, California, 91436, United States|Huntington Park, California, 90255, United States|Los Angeles, California, 90057, United States|Oakland, California, 94612, United States|Sacramento, California, 95821, United States|DeLand, Florida, 32720, United States|Miami Lakes, Florida, 33014, United States|Port Orange, Florida, 32129, United States|Tampa, Florida, 33606, United States|West Palm Beach, Florida, 33401, United States|Atlanta, Georgia, 30338, United States|Evanston, Illinois, 60201, United States|Flint, Michigan, 48504, United States|Omaha, Nebraska, 68114, United States|Bronx, New York, 10459, United States|Greensboro, North Carolina, 27408, United States|High Point, North Carolina, 27265, United States|Morehead City, North Carolina, 28557, United States|Cincinnati, Ohio, 45246, United States|Norman, Oklahoma, 73069, United States|Norman, Oklahoma, 73072, United States|Corpus Christi, Texas, 78413, United States|Houston, Texas, 77074, United States|Humble, Texas, 77338, United States|Hurst, Texas, 76054, United States|Katy, Texas, 77450, United States|San Antonio, Texas, 78209, United States|San Antonio, Texas, 78229, United States|Richland, Washington, 99352, United States
URL: https://clinicaltrials.gov/show/NCT02653599

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress